Contribute Try STAT+ Today

Seemingly overnight, the Food and Drug Administration appears to be taking a more risk-averse stance on drug reviews, leaving drug makers confused and their stock prices battered.

Acadia Pharmaceuticals said Monday evening that it was notified by the FDA about “deficiencies” in its application for an expanded use for its anti-psychosis drug Nuplazid. The company said the letter from the agency arrived on March 3 without any warning, exactly one month before Acadia was expecting a decision on Nuplazid’s approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.